Skip to main content
← All trials
Select Advanced Solid TumorsGeneticsFirst-in-humanBiologicalPhase 1

What this study is

CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.

What's being tested

  • CDR404

    Intervention · BIOLOGICAL

    IV infusions

Study details

Official title
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
Sponsor
CDR-Life AG
Conditions
Select Advanced Solid Tumors
Enrolling
42 people
Starts
2024-05-24
Est. completion
2027-12-31
Design
Open-label, sequential groups, Phase 1
Record
View on ClinicalTrials.gov ↗